Journal article
The novel adipokine CTRP1 is significantly associated with the incidence of major adverse cardiovascular events
Atherosclerosis, v 286, pp 1-6
Jul 2019
PMID: 31051410
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
The recently identified adiponectin paralogue C1q and tumor necrosis factor-related protein 1 (CTRP1) has been associated with obesity-linked disorders and coronary atherosclerosis. So far, the impact of circulating CTRP1 on the incidence of future cardiovascular events is unclear. Therefore, we aimed at investigating the association between CTRP1 and future cardiovascular risk.
We measured CTRP1 serum levels in 539 patients undergoing coronary angiography for the evaluation of established or suspected stable coronary artery disease (CAD). Prospectively, we recorded major adverse cardiovascular events (MACE), defined as the incidence of cardiovascular death, non-fatal myocardial infarction and non-fatal stroke over a follow-up period of 8 years.
At baseline, obesity, the metabolic syndrome, type 2 diabetes, and non-alcoholic fatty liver disease were significantly associated with increased CTRP1 (all p-values ≤0.001). Prospectively, MACE rates were lowest in the first quartile (15.3%) and increased over the second (23.7%) to the third and fourth quartile (each 29.0%; ptrend = 0.008). Moreover, after multivariable adjustment, CTRP1 was significantly associated with future MACE, with adjusted HRs of 1.83 [1.04–3.23]; p=0.037, 2.16 [1.25–3.75]; p=0.006, and 1.80 [1.03–3.15]; p=0.038, for CTRP1 quartiles two, three and four, respectively, when compared to quartile one.
We conclude that high serum levels of CTRP1 are significantly associated with future MACE.
[Display omitted]
•CTRP1 is associated with obesity-linked disorders.•CTRP1 is associated with future major adverse cardiovascular events.•CTRP1 is associated with cardiovascular risk beyond its association with obesity-linked disorders.
Metrics
Details
- Title
- The novel adipokine CTRP1 is significantly associated with the incidence of major adverse cardiovascular events
- Creators
- Axel Muendlein - Vorarlberg Institute for Vascular Investigation and TreatmentAndreas Leiherer - Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Feldkirch, AustriaChristoph Saely - Vorarlberg Institute for Vascular Investigation and TreatmentJanine Ebner - Vorarlberg Institute for Vascular Investigation and TreatmentKathrin Geiger - Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Feldkirch, AustriaEva Maria Brandtner - Vorarlberg Institute for Vascular Investigation and TreatmentAlexander Vonbank - Vorarlberg Institute for Vascular Investigation and TreatmentPeter Fraunberger - Medical Central Laboratories, Feldkirch, AustriaHeinz Drexel (Corresponding Author) - Drexel University, College of Medicine
- Publication Details
- Atherosclerosis, v 286, pp 1-6
- Publisher
- Elsevier B.V
- Number of pages
- 6
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- College of Medicine
- Web of Science ID
- WOS:000472708600001
- Scopus ID
- 2-s2.0-85064936814
- Other Identifier
- 991021860704104721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- International collaboration
- Web of Science research areas
- Cardiac & Cardiovascular Systems
- Peripheral Vascular Disease